Navigation Links
Raptor Pharmaceuticals Corp. to Present at Two Upcoming Healthcare Conferences
Date:10/28/2008

NOVATO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP), today announced that senior management will present a corporate overview and clinical pipeline updates at two upcoming healthcare investor conferences:

-- The 7th Annual BIO Investor Forum, to be held October 29-31, 2008 at the

Palace Hotel in San Francisco, CA. Raptor's presentation will take

place on Wednesday, October 29 at 4:45pm ET (1:45pm PT) in Telegraph

Hill. A live audio webcast of the presentation will be available at

http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=RAPTOR&item_id =1996013

-- The Rodman & Renshaw 10th Annual Healthcare Conference, to be held

November 10-12, 2008 at New York Palace Hotel in New York, NY.

Raptor's presentation will take place on Tuesday, November 11 at

9:30am ET (6:30am PT) in Holmes II (4th floor). A live audio webcast of

the presentation will be available at

http://www.wsw.com/webcast/rrshq14/rptp.ob

Both webcasts will be archived for 30 days and accessible through the investor relations section of Raptor's website at http://www.raptorpharma.com.

For more information on BIO Investor Forum conference please visit: http://investorforum.bio.org/opencms/bif/2008/

For more information on Rodman & Renshaw's 10th Annual Healthcare Conference please visit: http://www.rodmanandrenshaw.com/conferences

About Raptor Pharmaceuticals Corp.

Raptor Pharmaceuticals Corp. ("Raptor") is a publicly traded biotechnology company dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where it believes it may have the greatest impact. Raptor is involved in clinical development of its proprietary Delayed-Release Cysteamine ("DR Cysteamine") product candidate in nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease and Batten Disease, and its ConviviaTM product candidate in aldehyde dehydrogenase ("ALDH2") deficiency. In its preclinical programs Raptor bioengineers novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins which are designed to target cancer, neurodegenerative disorders and infectious diseases. Raptor's preclinical programs include HepTideTM, WntTideTM and NeuroTransTM.

For additional information, please visit http://www.raptorpharma.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: Raptor's ability to develop any of its preclinical and clinical drug product candidates. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our actual results to be materially different from these forward-looking statements. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products or acquiring products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able to raise sufficient funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in our filings from time to time with the Securities and Exchange Commission (the "SEC"), which we strongly urge you to read and consider, including our Registration Statement on Form S-1 that was declared effective on August 7, 2008; our annual report on Form 10-KSB filed with the SEC on November 14, 2007; and our Form 10-QSB filed with the SEC on July 9, 2008, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in our reports filed with the SEC. We expressly disclaim any intent or obligation to update any forward-looking statements.

For more information, please contact:

The Ruth Group

Sara Ephraim (investors)

(646) 536-7002

sephraim@theruthgroup.com

Janine McCargo (media)

(646) 536-7033

jmccargo@theruthgroup.com


'/>"/>
SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Glendale Raptors Join Four Points by Sheraton Denver Southeast and Animal Planets Dr. Kevin Fitzgerald for Second Annual Halloween Costume Drive & Halloween Party for Kunsberg School at National Jewish Medical and Research Center
2. The Glendale Raptors Set Dates for Youth Rugby League and USA Rugby Youth Academy
3. Smith & Nephew Endoscopys BIORAPTOR(TM) 2.3 PK Suture Anchor Provides Secure Repair for Shoulder, Hip Instability
4. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp.
5. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
6. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R)
9. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
10. CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development
11. Anadys Pharmaceuticals to Present at Bio Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s newest ... patients, standing as living proof that attitude and determination can combine into the ... that spike around the holidays. This campaign will offer patients a new-found hope, ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd ... Beach Resort and Spa in Honolulu, offering local frontline clinicians the opportunity to ... , The demand for supplemental training related to pain management has surged ...
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 ... to create versatile lower third titles with just a few clicks of the mouse," ... 2 includes 30 lower third animations. Choose from various styles with accented animations, rigid ...
(Date:12/2/2016)... Miami, FL (PRWEB) , ... December 02, 2016 , ... ... they are winners of $1,000 each from the National Family Partnership and the Drug ... winning families who decorated their homes and the 10 winning schools who decorated their ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... treatment has announced the opening of a new eating disorder treatment center location ... outpatient treatment for adults and adolescents, both males and females ages 10 and ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... SPRING, Md. , Dec. 2, 2016 ... new indication for Jardiance (empagliflozin) to reduce the risk ... diabetes mellitus and cardiovascular disease. "Cardiovascular ... with type 2 diabetes mellitus," said Jean-Marc Guettier ... and Endocrinology Products in FDA,s Center for Drug Evaluation ...
(Date:12/2/2016)... , December 2, 2016 ... global cardiac pacemaker market in its upcoming report titled, "Global Market Study ... a Declining CAGR of -1.4% between 2016 and 2024". The ... Mn in 2015 and this is likely to decline ... revenue, the global cardiac pacemaker market is anticipated to ...
(Date:12/2/2016)... , December 2, 2016 According to ... "Global Market Study on Automated Endoscope Reprocessors: Single Basin Automated ... of 8.6% Between 2016 and 2024 " the global automated endoscope reprocessors ... expected to expand at a CAGR of 7.2% during an ... US$ 1,367.6 Mn by 2024. ...
Breaking Medicine Technology: